BioLineRx Ltd.
BLRX · NASDAQ
11/24/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $14 | $18 | $236 | $684 |
| - Cash | $0 | $7 | $9 | $10 |
| + Debt | $0 | $13 | $14 | $15 |
| Enterprise Value | $14 | $23 | $241 | $688 |
| Revenue | $5 | $0 | $0 | $12 |
| % Growth | 1,526% | 19.2% | -97.8% | – |
| Gross Profit | $4 | $0 | $0 | $6 |
| % Margin | 83.4% | 76.3% | 86.7% | 48.2% |
| EBITDA | $0 | -$3 | $6 | $3 |
| % Margin | 0% | -1,147.4% | 2,240% | 26.4% |
| Net Income | -$6 | -$4 | $5 | -$3 |
| % Margin | -117.8% | -1,296.1% | 2,010.6% | -27.1% |
| EPS Diluted | -1.47 | -1 | 0.065 | -0.041 |
| % Growth | -47% | -1,650.4% | 259.3% | – |
| Operating Cash Flow | – | -$0 | -$3 | -$9 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | -$0 | -$3 | -$9 |